Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.

INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.

Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.

“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”

To read more on this topic click here.

For more information on Parkinson’s medication please visit the EPDA website.

Memory loss could be an indication of Parkinson’s

Last Month

Next Month

Go Back

Share this story

Comments

Advances

Apple Watch to detect Parkinson’s symptoms

The tech giant announced the news at a recent technology event

Parkinson’s 100 Challenge: the story so far…

A World Parkinson’s Day round-up from the challengers

“The beginning of a wonderful collaboration between countries, organisations and people”

The EPDA hosted a two-day event last week

Could a transplant lower the risk of Parkinson’s?

Researchers at Washington University School of Medicine, US, have found that having a heart, kidney, lung or bone marrow transplant could reduce the risk of developing Parkinson’s. As part of the study, published in medical journal ‘Parkinsonism & Related Disorders’, the team assessed data of just under 200,000 patients – 89,790 of whom had Parkinson’s. The results revealed that individuals who had a transplant were 37% less likely to develop Parkinson’s. This could be due to the immunosuppressant medication patients receive before undergoing a transplant, which researchers believe may help slow neurodegeneration as it reduces inflammation in the brain. The study said: “This study provides evidence that tissue transplant may be associated with a lower PD [Parkinson’s disease] risk, warranting further investigation to identify factors that mediate this relationship.”

Groundbreaking Parkinson’s trial publishes results

A breakthrough Parkinson’s trial that featured in a two-part documentary on UK television channel BBC Two has published its results. The study, which featured in the documentary ‘The Parkinson’s Drug Trial: A miracle cure?’, aimed to investigate whether it was possible to restore damaged neurons by administering protein Glial Cell Line Derived Neurotrophic Factor (GDNF). As part of the trial, scientists initially infused GDNF into the brains of six participants living with the condition. Researchers then invited a further 35 individuals with Parkinson’s to take part, with approximately half being administered with a placebo infusion. Although not conclusive, the results suggest that GDNF had an impact on the brain and researchers believe the topic is worthy of further study. Dr Alan Whone, principal investigator on the trial, said: “This represents some of the most compelling evidence yet that we may have a means to possibly reawaken and restore the dopamine brain cells…

Course for Parkinson’s nurses launches in Slovenia

The International Parkinson and Movement Disorder Society is hosting its third summer school for nurses specialising in Parkinson’s. The course – which will be held from 10-12 May in Ljubljana, Slovenia – will focus on the management of the motor and non-motor symptoms of the condition. Students will also attend lectures, examine Parkinson’s patients and discuss treatment plans with experts. All lectures will be presented in English. Heather Vitale, senior programme manager at the International Parkinson and Movement Disorder Society, said: “This course offers a unique opportunity for nurses to enhance their knowledge in Parkinson’s disease, while also learning and networking with their peers through case study presentations and small group discussions.” Registration closes 26 April 2019 and costs USD $350.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Phone
This field is for validation purposes and should be left unchanged.

Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Advances

Apple Watch to detect Parkinson’s symptoms

Europe

Parkinson’s 100 Challenge: the story so far…

Europe

“The beginning of a wonderful collaboration between countries, organisations and people”

Could a transplant lower the risk of Parkinson’s?

Groundbreaking Parkinson’s trial publishes results

Course for Parkinson’s nurses launches in Slovenia

{title}

Subscribe

Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Advances

Apple Watch to detect Parkinson’s symptoms

Europe

Parkinson’s 100 Challenge: the story so far…

Europe

“The beginning of a wonderful collaboration between countries, organisations and people”

Could a transplant lower the risk of Parkinson’s?

Groundbreaking Parkinson’s trial publishes results

Course for Parkinson’s nurses launches in Slovenia

{title}

Subscribe

Sign in